A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors.
Open accessThe DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index; 7 of the 30 sources its claims cite were checked for support.
Abstract
We found significant linkage to a locus that includes the XPNPEP2 candidate gene encoding membrane-bound APP. Mutation screening of this QTL identified a large coding deletion segregating in one pedigree and an upstream single-nucleotide polymorphism (C-2399A SNP) which regulates APP activity. We found significant association of this SNP to ACEi-induced AE.
Overview
CoChat Summary
TL;DR
A genomewide linkage and candidate-gene study found that plasma aminopeptidase P (APP) activity is partly heritable and links to the XPNPEP2 locus, where a C-2399A variant is associated with reduced APP activity and ACE inhibitor–induced angioedema. The authors conclude that this variant may contribute to susceptibility to a potentially fatal adverse drug reaction.
Key findings
- Plasma APP activity was heritable: 37.5% ± 26.5% in cohort 1 (P = .0336) and 33.6% ± 25.1% in all eight pedigrees combined (P = .0452).
- Variance-component linkage analysis found a maximum two-point LOD score of 3.75 at the XPNPEP2_CA marker near XPNPEP2 in combined cohorts 1 and 2.
- Mutation screening identified a 175-bp coding deletion (g.2953-3127del) in XPNPEP2 in one pedigree, predicted to produce a truncated 38-amino-acid protein, and an upstream C-2399A SNP segregating in seven of eight pedigrees.
- The C-2399A SNP significantly accounted for the linkage signal: excluding the deletion pedigree, the XPNPEP2_CA linkage LOD dropped from 3.24 to 0.54, and the SNP was a significant covariate (P < .0001; proportion of variance explained = 0.3149).
- In a case-control sample of 20 AE-ACEi cases and 60 controls, the A allele frequency was 27.3% in cases versus 11.1% in controls, with association P = .0364 by Armitage trend test.
Methods
- Eight white pedigrees (cohort 1: five pedigrees, 88 DNA samples; cohort 2: three pedigrees, 35 DNA samples; 123 participants total) were selected because one member per family had a history of ACEi-associated angioedema and/or anaphylactoid reaction. Plasma APP activity was measured as the quantitative trait.
- A 10-cM genomewide microsatellite scan (397 markers) enriched with seven markers around APP candidate regions was performed in cohort 1, followed by variance-component QTL linkage analysis in SOLAR; cohort 2 was genotyped for 11 markers covering regions with LOD > 1 and the XPNPEPL locus.
- Mutation detection used SSCP, sequencing, RFLP, and allele-specific PCR for XPNPEP2 and XPNPEPL; mRNA from lymphoblastoid cells was analyzed for the deletion’s splicing effect. The case-control association used 20 AE-ACEi cases and 60 controls matched by country of origin and gender.
Limitations
- The paper states that clinical diagnosis was not used in linkage analysis because of lack of power; controls were not matched for age; medical histories were unknown for US controls; and the biological significance of the C-2399A SNP remains undetermined.
- The paper also states that functional expression analysis was unsuccessful because XPNPEP2 is poorly expressed in human lymphoblastoid cells, and that further investigation of other linked loci is necessary.
- Evident from the text: the case-control association is small (20 cases, 60 controls) and not replicated; controls from Belgium and Canada had no history of ACEi therapy, so not all controls were ACEi-exposed; and only 9 of 20 AE-ACEi cases carried the identified variants, with one-third of cases having normal or high APP activity, indicating that the variant explains only a fraction of AE-ACEi risk.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
5 Valid · 1 Not valid · 15 Not checked · 34 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“These mean values for AEACEi patients differ from those previously reported in healthy whites (24 H11506 9 units and 19 H11506 7 units in women and men, respectively) (Cyr et al. 2001).”
What the sources say
- Supportedcites Cyr et al. 2001 source
The Methods (p. 3) identify the reference group as 116 healthy Caucasian volunteers. The Results (p. 5) report mean serum APP activity of 24 ± 9 in women and 19 ± 7 in men. The comparison with AE-ACEi patients is the citing authors’ own comparison, not a result attributed to this source. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Measured genotype analysis strongly suggests that the linkage signal for APP activity at this locus is accounted for predominantly by the SNP association.”
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found significant linkage (LOD p 3.75) to a locus that includes the XPNPEP2 candidate gene encoding membrane-bound APP.”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“With eight large pedigrees, we hereby demonstrate that this quantitative trait is partially regulated by genetic factors.”
boostedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, we show a significant association between the C-2399A polymorphism and AE-ACEi.”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
22 more claims
Create a free account to see all 55 claims and every source verdict.
- It may state two separate claims as one. 19
- Probably not a substantial claim. 19
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is similar to the estimated heritability of plasma APP of 37.5 ± 26.5% from a smaller study of eight pedigrees selected on the basis of one family member with ACEi-angioedema and/or other anaphylactoid responses to ACEi”
From A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor‐induced angioedema (2011) · cites this paper as Duan et al., 2005
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The frequency of the −2399A allele was also increased in 20 mixed-gender cases of ACE inhibitor-associated angioedema as compared to 60 ACE inhibitor-exposed controls.[11]”
From Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema (2010) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This variant segregated with reduced serum APP activity in families in which the proband had ACE inhibitor-associated angioedema or anaphylactoid reaction during dialysis.[11]”
From Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema (2010) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“this study also identified a QTL with peak LOD = 3.75 in the vicinity of the gene encoding APP (XPNPEP2) [Duan et al., 2005].”
From A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor‐induced angioedema (2011) · cites this paper as Duan et al., 2005
The cited source says what the claim attributes to it.
In the citing paper
“A single nucleotide polymorphism, −2399C>A (rs3788853, C-2399A), in XPNPEP2, the X-linked gene that encodes membranous APP, has been reported to associate with APP activity.”
From Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema (2010) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Introduction · p. 2
“The gene encoding the former is XPNPEP2 (MIM 300145), localized to chromosome Xq26.1 (Sprinkle et al. 1998)”
§ References · p. 10
“Assignment of the membrane-bound human aminopeptidase P gene (XPNPEP2) to chromosome Xq25.”
Citations
Cites
An Analysis of Transformations
Box, G. E. P., & Cox, D. R. (1964) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1964.tb00553.x · Cited by 15,052
Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites
Nielsen, H., Engelbrecht, J., Brunak, S., & von Heijne, G. (1997) · Protein Engineering Design and Selection · doi:10.1093/protein/10.1.1 · Cited by 5,356
Multipoint Quantitative-Trait Linkage Analysis in General Pedigrees
Almasy, L., & Blangero, J. (1998) · The American Journal of Human Genetics · doi:10.1086/301844 · Cited by 3,028
Bioregulation of kinins: kallikreins, kininogens, and kininases.
Bhoola, K. D., Figueroa, C. D., & Worthy, K. (1992) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00058-4 · Cited by 1,744
Angiotensin-Converting Enzyme Inhibitors
Brown, N. J., & Vaughan, D. E. (1998) · Circulation · doi:10.1161/01.cir.97.14.1411 · Cited by 958 · cited 1×
“Angiotensin I–converting enzyme inhibitors (ACEi) are a class of drugs used by 140 million patients worldwide for the treatment of cardiovascular diseases such as hypertension, congestive heart failure, and diabetes (Unger and Gohlke 1994; Brown and Vaughan 1998).”
BackgroundSelf-citationIsraili, Z. H., & Hall, W. D. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-3-234 · Cited by 910 · cited 2×
“7% of white patients (Israili and Hall 1992; Vleeming et al. 1998) and is four to five times more prevalent among”
BackgroundPlasma bradykinin in angio-oedema
Nussberger, J., Cugno, M., Amstutz, C., Cicardi, M., Pellacani, A., & Agostoni, A. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09137-x · Cited by 706
Self-citationAgostoni, A., Aygören-Pürsün, E., Binkley, K. E., Blanch, A., Bork, K., Bouillet, L., Bucher, C., Castaldo, A. J., Cicardi, M., Davis, A. E., et al. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.06.047 · Cited by 646
Self-citationTrans-acting regulatory variation in Saccharomyces cerevisiae and the role of transcription factors
Yvert, G., Brem, R. B., Whittle, J., Akey, J. M., Foss, E., Smith, E. N., Mackelprang, R., & Kruglyak, L. (2003) · Nature Genetics · doi:10.1038/ng1222 · Cited by 632
Kostis, J. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2003.09.014 · Cited by 579
Cited by
Cicardi, M., Aberer, W., Banerji, A., Bas, M., Bernstein, J. A., Bork, K., Caballero, T., Farkas, H., Grumach, A., Kaplan, A. P., et al. (2014) · Allergy · doi:10.1111/all.12380 · Cited by 666
Mangiafico, S., Costello-Boerrigter, L. C., Andersen, I. A., Cataliotti, A., & Burnett, J. C. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs262 · Cited by 276
“Similarly, individuals with XPNPEP2 genetic variations that result in lower APP levels are also more apt to have ACE-inhibitor-associated angioedema.(98,99) In this age of pharmacogenomics and personalized therapy, the incidence of angioedema may be decreased by not giving genetically predisposed subjects such a medic…”
BackgroundAngioedema without urticaria: a large clinical survey
Zingale, L. C., Beltrami, L., Zanichelli, A., Maggioni, L., Pappalardo, E., Cicardi, B., & Cicardi, M. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.060535 · Cited by 218
Factors predicting anaphylaxis to peanuts and tree nuts in patients referred to a specialist center
Summers, C. W., Pumphrey, R. S., Woods, C. N., McDowell, G., Pemberton, P. W., & Arkwright, P. D. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.12.003 · Cited by 185
New topics in bradykinin research
Maurer, M., Bader, M., Bas, M., Bossi, F., Cicardi, M., Cugno, M., Howarth, P., Kaplan, A., Kojda, G., Leeb‐Lundberg, F., et al. (2011) · Allergy · doi:10.1111/j.1398-9995.2011.02686.x · Cited by 176
“Why angioedema tends to recur in these patients is unclear but may be due to an abnormality in bradykinin degradation – as demonstrated for an APP variant (61) – which becomes clinically relevant when ACE is pharmacologically blocked.”
BackgroundSelf-citationAngiotensin-converting enzyme inhibitor-associated angioedema
Byrd, J. B., Adam, A., & Brown, N. J. (2006) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2006.08.001 · Cited by 160
Self-citationAngioedema Due to Bradykinin Dysregulation
Cicardi, M., & Zuraw, B. L. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.04.022 · Cited by 165
Cilia La Corte, A. L., Carter, A. M., Rice, G. I., Duan, Q. L., Rouleau, G. A., Adam, A., Grant, P. J., & Hooper, N. M. (2011) · Human Mutation · doi:10.1002/humu.21579 · Cited by 154
“-2399C>A was reported and associated with reduced plasma APP activity [Duan et al., 2005]; the present study therefore confirms an association of this polymorphism with plasma APP and identifies two novel polymorphisms also associated with plasma APP.”
BackgroundMethodInfluentialSelf-citationDipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema
Byrd, J. B., Touzin, K., Sile, S., Gainer, J. V., Yu, C., Nadeau, J., Adam, A., & Brown, N. J. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.096552 · Cited by 147
“16 Moreover, whereas the gene encoding for membrane-bound APP, the source of circulating APP activity, is X linked, 17 , 18 ACEi-associated angioedema is more common in women than in men.”
BackgroundSelf-citationFryer, R. M., Segreti, J., Banfor, P. N., Widomski, D. L., Backes, B. J., Lin, C. W., Ballaron, S. J., Cox, B. F., Trevillyan, J. M., Reinhart, G. A., et al. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707641 · Cited by 130
“…primary mechanism responsible for the large depressor response in rats (and subsequent angioedema in patients); a finding consistent with increased susceptibility to angioedema in patients with low APP activity on ACE inhibitor therapy (Adam et al., 2002; Duan et al., 2005; Nikpoor et al., 2005).”
BackgroundGenetics of Hereditary Angioedema Revisited
Germenis, A. E., & Speletas, M. G. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8543-x · Cited by 149
Hoover, T. A., Lippmann, M. L., Grouzmann, E., Marceau, F., & Herscu, P. (2009) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2009.03323.x · Cited by 139
Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema
Beltrami, L., Zanichelli, A., Zingale, L. C., Vacchini, R., Carugo, S., & Cicardi, M. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834b4b9b · Cited by 126
Drouet, C., Désormeaux, A., Robillard, J., Ponard, D., Bouillet, L., Martin, L., Kanny, G., Moneret-Vautrin, D.-A., Bosson, J.-L., Quesada, J.-L., et al. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.10.048 · Cited by 112
Self-citationACE inhibitor-mediated angioedema
Montinaro, V., & Cicardi, M. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.106081 · Cited by 107
Woodard-Grice, A. V., Lucisano, A. C., Byrd, J. B., Stone, E. R., Simmons, W. H., & Brown, N. J. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833d3acb · Cited by 92
Self-citationGenetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema
Pare, G., Kubo, M., Byrd, J. B., McCarty, C. A., Woodard-Grice, A., Teo, K. K., Anand, S. S., Zuvich, R. L., Bradford, Y., Ross, S., et al. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328363c137 · Cited by 87
Self-citationRecent Advances in Drug-Induced Angioedema
Inomata, N. (2012) · Allergology International · doi:10.2332/allergolint.12-rai-0493 · Cited by 88
Pharmacogenomics of off‐target adverse drug reactions
Garon, S. L., Pavlos, R. K., White, K. D., Brown, N. J., Stone, C. A., & Phillips, E. J. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13294 · Cited by 75
Self-citationMahmoudpour, S. H., Leusink, M., van der Putten, L., Terreehorst, I., Asselbergs, F. W., de Boer, A., & der Zee, A. H. M. (2013) · Pharmacogenomics · doi:10.2217/pgs.12.206 · Cited by 71
Angiotensin-Converting Enzyme Inhibitors and Angioedema
Sánchez‐Borges, M., & González-Aveledo, L. (2010) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2010.2.3.195 · Cited by 75
“Furthermore, a polymorphism of XPNPEP2 (the -2399 A variant), a candidate gene encoding membrane-bound APP, is associated with reduced APP activity and a higher incidence of ACEI-induced angioedema.(12) Angioedema associated with ACEIs is most commonly observed at the beginning of treatment, but it may also develop Or…”
BackgroundAngiotensin-converting enzyme inhibitor-related angioedema: how to deal with it
Beltrami, L., Zingale, L. C., Carugo, S., & Cicardi, M. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.5.643 · Cited by 66
“It is likely that changes in the enzymes intervening in bradykinin catabolism (ACE, carboxypeptidase N, aminopeptidase P) represent factors predisposing to the development of ACE inhibitor-related angioedema [20-26].”
BackgroundFactor XII mutations, estrogen-dependent inherited angioedema, and related conditions
Binkley, K. E. (2010) · Allergy Asthma and Clinical Immunology · doi:10.1186/1710-1492-6-16 · Cited by 58
Angioedema induced by angiotensin-converting enzyme inhibitors
Campo, P., Fernández, T. D., Cantó, G., & Mayorga, C. (2013) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e328362b835 · Cited by 68
“There are several studies [46,58] indicating that different polymorphisms of X-prolyl aminopeptidase 2 (XPNPEP2), a candidate gene encoding membrane-bound APP, are associated with ACEIinduced angioedema, being more common in women.”
BackgroundAngiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema
Stone, C. A., & Brown, N. J. (2017) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2017.04.006 · Cited by 65
Self-citationDésormeaux, A., Moreau, M. E., Lepage, Y., Chanard, J., & Adam, A. A. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2007.11.019 · Cited by 58
Self-citationDuan, Q., Binkley, K. E., & Rouleau, G. A. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.12.010 · Cited by 61
“5% agarose gel for genotype calling.(20) Duan et al(20) had previously determined the high efficacy and reproducibility of this allele-specific genotyping method through comparisons with sequencing results in more than 300 DNA samples.”
BackgroundMethodInfluentialSelf-citationGrilo, A., Sáez-Rosas, M. P., Santos-Morano, J., Sánchez, E., Moreno‐Rey, C., Real, L. M., Ramírez‐Lorca, R., & Sáez, M. E. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328341041c · Cited by 56
“Nuts and Bolts” of Laboratory Evaluation of Angioedema
Farkas, H., Veszeli, N., Kajdácsi, E., Cervenak, L., & Varga, L. Á. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8539-6 · Cited by 60
Bernstein, J. A., Moellman, J. J., Collins, S. P., Hart, K. W., & Lindsell, C. J. (2015) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2014.12.007 · Cited by 49
Towards Triple Vasopeptidase Inhibitors for the Treatment of Cardiovascular Diseases
Daull, P., Jeng, A. Y., & Battistini, B. J. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31813c6ca5 · Cited by 52
Chavan, S., Mangalaparthi, K. K., Singh, S., Renuse, S., Vanderboom, P. M., Madugundu, A. K., Budhraja, R., McAulay, K., Grys, T. E., Rule, A. D., et al. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00391 · Cited by 44
Bradykinin-Mediated Angioedema: An Update of the Genetic Causes and the Impact of Genomics
Marcelino-Rodríguez, I., Callero, A., Mendoza-Álvarez, A., Perez-Rodriguez, E., Barrios-Recio, J., García-Robaina, J. C., & Flores, C. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00900 · Cited by 42
Cicardi, M., & Johnston, D. T. (2012) · Acta Haematologica · doi:10.1159/000336590 · Cited by 41
Icatibant, the bradykinin B2 receptor antagonist with target to the interconnected kinin systems
Charignon, D., Späth, P., Martin, L., & Drouet, C. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.723692 · Cited by 44
“The defective APP and DPPIV activities are most often associated with iatrogenic AE [16,41] or with a risk factor for the development of severe form of HAE [42,43].”
BackgroundMoholisa, R. R., Rayner, B. R., Patricia Owen, E., Schwager, S. L. U., Stark, J. S., Badri, M., Cupido, C. L., & Sturrock, E. D. (2013) · The Journal of Clinical Hypertension · doi:10.1111/jch.12104 · Cited by 42
“BK is primarily degraded by ACE and secondarily by aminopeptidase P (APP).(8,9) During ACE inhibition, BK is primarily degraded by APP.”
BackgroundBradykinin Metabolism and Drug-Induced Angioedema
Smolińska, S., Antolín‐Amérigo, D., & Popescu, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411649 · Cited by 52
“In other populations, genetic polymorphisms in the XPNPEP2 gene that encodes APP reduce plasma APP activity with higher levels of BK and des-Arg9-BK, and are associated with a higher occurrence of ACEI-AE [34,35].”
BackgroundRizzolio, F., Sala, C. F., Alboresi, S., Bione, S., Gilli, S., Goegan, M., Pramparo, T., Zuffardi, O., & Toniolo, D. (2007) · Human Genetics · doi:10.1007/s00439-007-0329-z · Cited by 39
“The XPNPEP2 gene, in Xq25 (Prueitt et al. 2000) and the POF1B gene in Xq21 (Bione et al. 2004, p. 264) were highly expressed in kidney and adipocytes (Duan et al. 2005) or in the granular layer of the epidermis and in few epithelia (Rizzolio et al. 2006b), respectively.”
BackgroundAngioedema and angiotensin‐converting enzyme inhibitors: Are demographics a risk?
Davis, E. M., & Devaiah, A. K. (2008) · Otolaryngology · doi:10.1016/j.otohns.2008.03.029 · Cited by 38
“membrane-bound aminopeptidase.(8) Although further genetic studies are necessary to solidify these etiologies of ACEI-induced angioedema, it seems clear based on demographic data presented here and preliminary genetic data cited in other studies that black patients are at a higher risk for ACEI-induced angioedema.”
BackgroundAn update on the pharmacogenetics of treating hypertension
Fontana, V., Luizon, M. R., & Sandrim, V. C. (2014) · Journal of Human Hypertension · doi:10.1038/jhh.2014.76 · Cited by 37
Battistini, B. J., Daull, P., & Jeng, A. Y. (2006) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2005.tb00175.x · Cited by 36
Rasmussen, E. R., Hallberg, P., Baranova, E. V., Eriksson, N., Karawajczyk, M., Johansson, C. U., Cavalli, M., Maroteau, C., Veluchamy, A., Islander, G., et al. (2020) · The Pharmacogenomics Journal · doi:10.1038/s41397-020-0165-2 · Cited by 34
Les angiœdèmes bradykiniques héréditaires ou acquis
Bouillet, L., Boccon‐Gibod, I., & Massot, C. (2010) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2009.11.021 · Cited by 31
Kinin-dependent hypersensitivity reactions in hemodialysis: metabolic and genetic factors
Molinaro, G., Duan, Q. L., Chagnon, M., Moreau, M. E., Simon, P., Clavel, P., Lavaud, S., Boileau, G., Rouleau, G. A., Lepage, Y., et al. (2006) · Kidney International · doi:10.1038/sj.ki.5001873 · Cited by 29
“In addition, we observed a deletion of 175 bp in one case of AE.”
BackgroundResultInfluentialSelf-citationMoreau, M. E., Dubreuil, P., Molinaro, G., Chagnon, M., Müller‐Esterl, W., Lepage, Y., Marceau, F., & Adam, A. A. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.088005 · Cited by 37
Self-citationGulec, M., Çalışkaner, Z., Tunca, Y., Ozturk, S., Bozoğlu, E., Gül, D., Erel, F., Kartal, Ö., & Karaayvaz, M. (2008) · Allergologia et Immunopathologia · doi:10.1016/s0301-0546(08)72537-0 · Cited by 27
“22 Angioedema due to ACEi and ATRB are not usually taken under control following cease of the drug with antihistamines and corticosteroid treatment, 17 although some patients may respond to treatment.”
InfluentialHereditary angioedema with F12 mutation
Piñero-Saavedra, M., Gonzalez‐Quevedo, T., Pedro, B. S. D. S., Alcaraz, C., Bobadilla-González, P., Fernández-Vieira, L., Hinojosa, B., & García-Lozano, R. (2016) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2016.09.001 · Cited by 28
Life-threatening angio-oedema and death associated with the ACE inhibitor enalapril.
Cupido, C., & Rayner, B. L. (2007) · PubMed · Cited by 24
Ghouse, J., Ahlberg, G., Andreasen, L., Banasik, K., Brunak, S., Schwinn, M., Larsen, I. H., Petersen, O., Sørensen, E., Ullum, H., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.05.054 · Cited by 24
Pharmacogenetics of angiotensin‐converting enzyme inhibitor‐induced angioedema
Liau, Y., Chua, I. C., Kennedy, M. A., & Maggo, S. D. S. (2018) · Clinical & Experimental Allergy · doi:10.1111/cea.13326 · Cited by 28
“To date, one genome‐wide association study and several candidate gene studies have been published on the association of genetic variation with ACEi‐A. Genetic associations reported have been attributed to several distinct mechanisms: (a) genes coding for alternative enzymes responsible for the degradation of bradykini…”
BackgroundMethodResultInfluentialMahmoudpour, S. H., Veluchamy, A., Siddiqui, M. K., Asselbergs, F. W., Souverein, P. C., de Keyser, C. E., Albert Hofman, D., Lang, C. C., Doney, A. S. F., Stricker, B. H. C., et al. (2016) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000264 · Cited by 21
“Studies on ACE-inhibitor induced angioedema have also been conducted with the same approach; 3 of them found a statistically significant association between ACE-inhibitor induced angioedema and single nucleotide polymorphisms (SNPs) in the XPNPEP2 gene [16-18].”
ResultMaroteau, C., Siddiqui, M. K., Veluchamy, A., Carr, F., White, M., Cassidy, A. J., Baranova, E. V., Rasmussen, E. R., Eriksson, N., Bloch, K. M., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1927 · Cited by 21
Self-citationWadelius, M., Marshall, S. E., Islander, G., Nordang, L., Karawajczyk, M., Yue, Q.-Y., Terreehorst, I., Baranova, E. V., Hugosson, S., Sköldefors, K., et al. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.138 · Cited by 30
Leveraging Genetics for Hereditary Angioedema: A Road Map to Precision Medicine
Germenis, A. E., Rijavec, M., & Veronez, C. L. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08836-7 · Cited by 26
(2013) · doi:10.1016/j.iac.2013.07.001 · Cited by 19
Icatibant in angiotensin‐converting enzyme ( ACE ) inhibitor‐associated angioedema
Fok, J. S., Katelaris, C. H., Brown, A. F., & Smith, W. (2015) · Internal Medicine Journal · doi:10.1111/imj.12799 · Cited by 19
Renin–angiotensin system inhibitors and angioedema: anesthetic implications
Stojiljković, L. (2012) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0b013e328352dda5 · Cited by 21
XPNPEP2 is overexpressed in cervical cancer and promotes cervical cancer metastasis
Cheng, T., Wei, R., Jiang, G., Zhou, Y., Lv, M., Dai, Y., Yuan, Y., Luo, D., Ma, D., Li, F., et al. (2017) · Tumor Biology · doi:10.1177/1010428317717122 · Cited by 19
Distinct Conditions Support a Novel Classification for Bradykinin-Mediated Angio-Oedema
Dessart, P., Defendi, F., Humeau, H., Nicolie, B., Sarre, M. E., Charignon, D., Ponard, D., Cichon, S., Drouet, C., & Martin, L. (2015) · Dermatology · doi:10.1159/000371814 · Cited by 17
XPNPEP2 is associated with lymph node metastasis in prostate cancer patients
Li, F., Dai, Y., Xu, H., Huang, K., Zhou, Y., Luo, D., Ma, D., Xi, L., Lv, M., & Ma, X. (2019) · Scientific Reports · doi:10.1038/s41598-019-45245-5 · Cited by 18
Misumi, Y., & Ikehara, Y. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382219-2.00745-6 · Cited by 20
Hereditary angioedema: Assessing the hypothesis for underlying autonomic dysfunction
Wu, M. A., Casella, F., Perego, F., Suffritti, C., Afifi, N. A., Tobaldini, E., Zanichelli, A., Cogliati, C. B., Montano, N., & Cicardi, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187110 · Cited by 17
Disease-modifying factors in hereditary angioedema: an RNA expression-based screening
López‐Lera, A., Sánchez‐Cabo, F., Garrido, S., Dopazo, A., & López‐Trascasa, M. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-77 · Cited by 15
“PBMCs synthesis of C1-INH mRNA, nor that of other molecules classically implicated in the pathogenesis of HAE like Angiotensin Converting Enzyme (ACE), Bradykinin Receptors 1 and 2, (BDKR1, BDKR2) or Aminopeptidase P (APP) showed any statistical effect on the frequency of HAE attacks [18,19].”
BackgroundAli, H. A., Lomholt, A. F., Mahmoudpour, S. H., Hermanrud, T., Bygum, A., von Buchwald, C., Jakobsen, M. A., & Rasmussen, E. R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224858 · Cited by 15
“Since it has been shown that a low plasma activity of APP could be a predisposing factor for the development of angioedema during ACEi treatment [26], in three studies the polymorphism XPNPEP2 of the APP gene was investigated, and a significant association with ACEi-AE was identified consistently in all three studies…”
BackgroundResultRoskiewicz, F., Andriamanana, I., Gras‐Champel, V., Andréjak, M., & Massy, Z. A. (2007) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2007.03.003 · Cited by 14
Duplication of OCRL and adjacent genes associated with autism but not Lowe syndrome
Schroer, R. J., Beaudet, A. L., Shinawi, M. S., Sahoo, T., Patel, A., Sun, Q., Skinner, C. D., & Stevenson, R. E. (2012) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.35566 · Cited by 15
Cugno, M., Consonni, D., Lombardi, A., Bono, P., Oggioni, M., Renteria, S. U., Pesatori, A. C., Castaldi, S., Riboldi, L., Bordini, L., et al. (2021) · Vaccines · doi:10.3390/vaccines9091011 · Cited by 12
“Considering that bradykinin is mainly catabolized by ACE, subjects taking ACE inhibitors may have higher levels of bradykinin, leading to an increase in vascular permeability [21,22], especially in the presence of reduced levels in other catabolic enzymes [23,24].”
BackgroundSelf-citationPharmacogenetics in Cardiovascular Disease: The Challenge of Moving From Promise to Realization
Joseph, P. G., Paré, G., Ross, S. A., Roberts, R., & Anand, S. S. (2013) · Clinical Cardiology · doi:10.1002/clc.22200 · Cited by 12
(2012) · doi:10.5858/arpa.2011-0466-oa · Cited by 12
“Notably, the XPNPEP2 gene responsible for coding membrane-bound APP is polymorphic.(14,15) The C-2399A single-nucleotide polymorphism (SNP) in XPNPEP2 results in a substantially truncated APP protein that cannot adequately bind to the membrane of host epithelial cells, thereby reducing its ability to participate in br…”
BackgroundOutpatient management of chronic heart failure
Kaldara, E. E., Sanoudou, D., Adamopoulos, S. N., & Nanas, J. N. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.978286 · Cited by 13
“Further, a polymorphism of XPNPEP2, a protein-coding gene, is associated with reduced APP activity and a higher incidence of ACEI-induced angioedema [31].”
BackgroundArzneimittelassoziierte Angioödeme: Bradykinin im Fokus
Sachs, B., Meier, T., Nöthen, M. M., Stieber, C., & Stingl, J. (2018) · Der Hautarzt · doi:10.1007/s00105-017-4119-9 · Cited by 11
Precision Medicine and Adverse Drug Reactions Related to Cardiovascular Drugs
Noyes, J. D., Mordi, I. R., Doney, A. S. F., Jamal, R., & Lang, C. C. (2021) · Diseases · doi:10.3390/diseases9030055 · Cited by 10
“The XPNPEP2 gene codes for APP, and it has been shown that a variant of this gene was more prevalent in cases of ACEi angioedema compared to controls [18].”
BackgroundAbstracts from the 10th C1-inhibitor deficiency workshop
Schmaier, A., Cicardi, M., Reshef, A., Moldovan, D., Mócsai, A., López-Trascasa, M., Lera, A. L., Brown, N., Germenis, A., Filippelli-Silva, R., et al. (2017) · Allergy, Asthma & Clinical Immunology · doi:10.1186/s13223-017-0198-5 · Cited by 8
Self-citationLevy, J., Rivard, G., Wagner, É., Beezhold, D. H., Berlin, N., Li, F., Zhang, Z., & Sussman, G. (2014) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-014-0060-y · Cited by 9
“2953-3127del) [22].”
Fatal laryngeal angioedema: a case report and a workup of angioedema in a forensic setting
Krizova, A., Gardner, T. R., Little, D., Arcieri-Piersanti, V., & Pollanen, M. S. (2015) · Forensic Science Medicine and Pathology · doi:10.1007/s12024-015-9701-9 · Cited by 9
“also been demonstrated [45] and linked to ACEI-induced angioedema.”
Background2 Molecular and genetic aspects of the kallikrein-kinin system
Alhenc‐Gelas, F., & Girolami, J. P. (2011) · De Gruyter eBooks · doi:10.1515/9783110252354.7 · Cited by 9
Altoum, S. M., Al-Mahayri, Z. N., & Ali, B. R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1286494 · Cited by 10
“Combined with ACE inhibition, this reduction leads to the accumulation of mediators, resulting in ACEIs-AE (Duan et al., 2005; Woodard-Grice et al., 2010).”
BackgroundInfluentialAngiotensin-converting Enzyme Inhibitor Angioedema Requiring Admission to an Intensive Care Unit
Hoo, G. W. S., Lin, H. K., Junaid, I., & Klaustermeyer, W. B. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.02.006 · Cited by 9
Hermanrud, T., Duus, N., Bygum, A., & Rasmussen, E. R. (2016) · Case Reports in Emergency Medicine · doi:10.1155/2016/3930923 · Cited by 9
Adam, A. A., Désormeaux, A., & Moreau, M. E. (2007) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)32963-2 · Cited by 11
Self-citationVasoactive mediators and hypotensive transfusion reactions
Eastlund, T. (2007) · Transfusion · doi:10.1111/j.1537-2995.2007.01154.x · Cited by 8
“There is recessive inheritance of APP levels as well as susceptibility to ACEi-related angioneurotic edema and ACEi-related hypotensive reactions during dialysis.(28,29) Families of patients experiencing ACEi-related hypotensive reactions during transfusion and during therapeutic apheresis procedures have not yet been…”
BackgroundCaballero, T., Cabañas, R., Campos, A., Cimbollek, S., Gómez‐Traseira, C., Gonzalez‐Quevedo, T., Guilarte, M., Palomo, J. J., Larco, J., López‐Trascasa, M., et al. (2011) · Cited by 9
Cardiovascular Instability Preceded by Orolingual Angioedema after Alteplase Treatment
Kageyama, T., Okanoue, Y., Takai, R., & Suenaga, T. (2016) · Internal Medicine · doi:10.2169/internalmedicine.55.4772 · Cited by 6
“It has recently been shown that the polymorphism of the APP gene is related to the occurrence of ACE inhibitor-associated angioedema (7, 8).”
BackgroundGenetic Risk of Diverticular Disease Predicts Early Stoppage of Nicorandil
(2020) · doi:10.1002/cpt.1941 · Cited by 6
“In support of this approach is identification of the SLCO1B1 variant that is associated with statin intolerance(4) and the rs3788853 variant of XPNPEP2 that may be associated with angiotensin-converting enzyme inhibitor-related angioedema.(5) Recent genomewide association studies have identified genetic variants assoc…”
BackgroundPharmacogenetics of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema
Pall, A. H., Rasmussen, E. R., & Wadelius, M. (2021) · Pharmacogenomics · doi:10.2217/pgs-2021-0036 · Cited by 6
Drouet, C., Ponard, D., & Bouillet, L. (2006) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2006.03.012 · Cited by 6
Classification et diagnostic biologique des angioedèmes
Drouet, C., Ponard, D., Monnier, N., Lunardi, J., & Bosson, J.-L. (2008) · Revue Française d Allergologie et d Immunologie Clinique · doi:10.1016/j.allerg.2008.02.004 · Cited by 5
5 Drugs in the kallikrein-kinin system
Marceau, F. (2011) · De Gruyter eBooks · doi:10.1515/9783110252354.69 · Cited by 4
Papapostolou, N., Gregoriou, S., Katoulis, A., & Makris, M. P. (2024) · Pharmaceuticals · doi:10.3390/ph17030360 · Cited by 6
“Beyond genetic factors, various environmental factors can also contribute to angioedema presentation [42].”
BackgroundThe Incidence and Frequency of Various Causes of Angioedema in Emergency Medicine
Karadža‐Lapić, L., Pikivaca, T., Pervan, P., Zlatović, J. J., Delin, S., & Prkačin, I. (2018) · Acta Medica Academica · doi:10.5644/ama2006-124.210 · Cited by 4
Du-Thanh, A., Raison‐Peyron, N., & Guillot, B. (2011) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2010.12.017 · Cited by 3
Moreau, M. E., & Adam, A. A. (2006) · Annales Pharmaceutiques Françaises · doi:10.1016/s0003-4509(06)75320-2 · Cited by 5
Self-citationSychev, I. V., Денисенко, Н. П., Kachanova, A. A., Lapshtaeva, A. V., Abdullaev, S. P., Goncharova, L. N., Mirzaev, K. B., & Sychev, D. A. (2023) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-230006 · Cited by 7
“The genetically conditioned decreased activity of aminopeptidase P can associate with the higher risk of the ACEI-induced angioedema [33,35].”
Coleman, J. J., & Cox, A. R. (2014) · Side effects of drugs annual · doi:10.1016/b978-0-444-62635-6.00020-6 · Cited by 5
Simmons, W. H. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382219-2.00344-6 · Cited by 5
Roy, C. S., Marceau, E., Gera, L., & Marceau, F. (2011) · Vascular Pharmacology · doi:10.1016/j.vph.2011.09.003 · Cited by 4
Exploration biologique des angiœdèmes à kinines
Defendi, F., Charignon, D., Ghannam, A., Ponard, D., & Drouet, C. (2015) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2015.01.018 · Cited by 4
Naik, H., O'connor, M., Sanderson, S. C., Pinnell, N. E., Dong, M., Wiegand, A., Obeng, A. O., Abul‐Husn, N. S., & Scott, S. A. (2009) · Pharmacogenomics · doi:10.2217/pgs-2023-0191 · Cited by 4
Réactions d’hypersensibilité en hémodialyse
Chanard, J. (2008) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2008.04.002 · Cited by 2
Self-citation
Metadata
- Authors
- Duan, Q. L., Nikpoor, B., Dubé, M.-P., Molinaro, G., Meijer, I. A., Dion, P., Rochefort, D., Saint-Onge, J., Flury, L., Brown, N. J., Gainer, J. V., Rouleau, J. L., Agostoni, A., Cugno, M., Simon, P., Clavel, P., Potier, J., Wehbe, B., Benarbia, S., Marc-Aurèle, J., Chanard, J., Foroud, T., Adam, A., & Rouleau, G. A.
- Affiliations
- Hôpital Notre-Dame (CA)
- Montreal Heart Institute (CA)
- Université de Montréal (CA)
- Vanderbilt University (US)
- University of Milan (IT)
- Centre Hospitalier de Saint-Brieuc (FR)
- Centre Hospitalier Universitaire de Reims (FR)
- Centre Hospitalier de Cornouaille (FR)
- Hôpital de Saint-Jérôme (CA)
- Indiana University Indianapolis (US)
- Corresponding author
- Rouleau, Guy A.
- ORCID
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2005-10
- Volume
- 77
- Issue
- 4
- Pages
- 617-626
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC1275610
- OpenAlex
- W2141319262
- Cited by
- 126
- References
- 43
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 4 · 2023: 3 · 2021: 6 · 2020: 4 · 2019: 5 · 2018: 5 · 2017: 6 · 2016: 8 · 2015: 8 · 2014: 8 · 2013: 8 · 2012: 11
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 2848 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Funders
- McGill University
- National Institutes of Health
- Canadian Institutes of Health Research
- National Heart, Lung, and Blood Institute (R01HL079184)
- Topics
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- angioedema, ACE inhibitors, aminopeptidase P, genetic susceptibility, single nucleotide polymorphisms, linkage analysis, quantitative trait loci, plasma enzyme activity, adverse drug reactions
- MeSH terms
- Aminopeptidases, Angioedema, Angiotensin-Converting Enzyme Inhibitors, Female, Humans, Genetic Linkage, Male, Mutation, Pedigree, Cohort Studies, Quantitative Trait Loci
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.